Objectives: To assess the temporal trends in the use of second antiseizure (ASM) regimens and compare the efficacy of substitution monotherapy and combination therapy after failure of initial monotherapy in people with epilepsy.Methods: This was a longitudinal observational cohort study conducted at the Epilepsy Unit of the Western Infirmary in Glasgow, Scotland. We included patients who were newly treated for epilepsy with ASMs between July 1982, and October 2012. All patients were followed up for a minimum of 2 years. Seizure freedom was defined as no seizure for at least 1 year on unchanged medication at the last follow up.Results: During the study period, 498 patients were treated with a second ASM regimen after failure of the initial ASM monotherapy, of whom 346 (69%) were prescribed combination therapy and 152 (31%) were given substitution monotherapy. The proportion of patients receiving second regimen as combination therapy increased during the study period from 46% in first epoch (1985–1994) to 78% in the last (2005–2015) (RR = 1.66, 95% CI: 1.17–2.36, corrected‐p = .010). Overall, 21% (104/498) of the patients achieved seizure freedom on the second ASM regimen, which was less than half of the seizure‐free rate on the initial ASM monotherapy (45%, p < .001). Patients who received substitution monotherapy had similar seizure‐free rate compared with those who received combination therapy (RR = 1.17, 95% CI: 0.81–1.69, p = .41). Individual ASMs used, either alone or in combination, had similar efficacy. However, the subgroup analysis was limited by small sample sizes.Significance: The choice of second regimen used based on clinical judgment was not associated with treatment outcome in patients whose initial monotherapy failed due to poor seizure control. Alternative approaches such as machine learning should be explored to aid individualized selection of the second ASM regimen.
Background The rheumatoid arthritis is one of the most severe and widespread systemic inflammatory autoimmune diseases. The biomarkers play an important role in early diagnostics, activity evaluation, severity of disease course, disease prognosis and effectiveness of applied therapy. Traditional inflammatory biomarkers such as ESR (erythrocyte sedimentation rate) and CRP (c-reactive protein) can be in the normal range in approximately 40% of RA patients. MBDA has been proposed as an objective measure of disease activity for patients with RA. MBDA is a cumulative score based on the serum concentrations of 12 serum proteins (biomarkers); the score has been validated for use in RA. MBDA can provide a baseline assessment of RA disease activity and track it over time. But Interpretation of individual biomarker results has not been validated. Objectives To compare the MBDA (VECTRA-DA) scores with traditional serologic markers of inflammation (ESR, CRP), as well as the relative contribution of the individual cytokines comprising the MBDA, for the assessment of RA activity in a real life clinical practice setting. Methods A retrospective chart review study was conducted in an urban teaching hospital and 150 patients with RA were identified, fulfilling the 2010 ACR diagnostic criteria. The study was approved by the ethics committee, and simultaneous blood draws were performed for Vectra-DA, ESR and CRP during routine clinic visits over a period of one year. We compared the VECTRA test results in Rheumatoid Arthritis patients with ESR and CRP (Table 1) and analyzed the contribution of the individual components of the MBDA toward its composite score. Results see Table 1. The log of each variable predicting Vectra. The effect is additive. For every increase in log(Variable) by 1 (which is a real increase in the variable by about 2.72 times) the Vectra score increases by Effect Conclusions The novel MBDA test VECTRA-DA provides additional information, beyond the traditional serologic markers of inflammation ESR and CRP, toward the assessment of RA disease activity. VCAM, TNF-RI and IL-6 levels appear to have a major influence on the composite MBDA score that is associated with disease activity. Disclosure of Interest S. Chittalae: None declared, O. Shuaib: None declared, H. Hakeem: None declared, S. Kadavath: None declared, M. Briggs: None declared, P. Efthimiou Consultant for: crescendo bioscience